Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hemangioma, Cavernous, Central Nervous System | 38 | 2024 | 223 | 7.820 |
Why?
|
Hemangioma, Cavernous | 8 | 2021 | 69 | 2.510 |
Why?
|
Cerebral Hemorrhage | 10 | 2023 | 325 | 2.020 |
Why?
|
Brain Neoplasms | 9 | 2023 | 763 | 1.670 |
Why?
|
Biomarkers | 13 | 2023 | 1709 | 1.520 |
Why?
|
Apoptosis Regulatory Proteins | 12 | 2023 | 199 | 1.090 |
Why?
|
Capillary Permeability | 3 | 2021 | 130 | 0.860 |
Why?
|
Receptors, Nerve Growth Factor | 1 | 2020 | 11 | 0.780 |
Why?
|
Hemorrhage | 8 | 2023 | 265 | 0.760 |
Why?
|
Intracranial Hemorrhages | 6 | 2021 | 119 | 0.750 |
Why?
|
Data Mining | 1 | 2020 | 42 | 0.740 |
Why?
|
rho-Associated Kinases | 6 | 2019 | 159 | 0.740 |
Why?
|
Neurodegenerative Diseases | 1 | 2020 | 43 | 0.740 |
Why?
|
Metabolic Networks and Pathways | 1 | 2020 | 78 | 0.740 |
Why?
|
Disease Models, Animal | 9 | 2021 | 2227 | 0.700 |
Why?
|
Gene Regulatory Networks | 2 | 2020 | 291 | 0.670 |
Why?
|
KRIT1 Protein | 9 | 2023 | 62 | 0.650 |
Why?
|
Brain Injuries | 1 | 2020 | 160 | 0.640 |
Why?
|
Brain | 9 | 2020 | 2211 | 0.630 |
Why?
|
Iron | 3 | 2018 | 163 | 0.620 |
Why?
|
Nerve Tissue Proteins | 1 | 2020 | 503 | 0.610 |
Why?
|
X-Ray Microtomography | 2 | 2019 | 79 | 0.600 |
Why?
|
Transcriptome | 5 | 2024 | 574 | 0.580 |
Why?
|
Magnetic Resonance Imaging | 15 | 2023 | 3347 | 0.580 |
Why?
|
Vascular Endothelial Growth Factor A | 5 | 2024 | 407 | 0.570 |
Why?
|
Cholesterol, HDL | 1 | 2016 | 165 | 0.530 |
Why?
|
Seizures | 1 | 2017 | 293 | 0.520 |
Why?
|
Vitamin D | 1 | 2016 | 261 | 0.470 |
Why?
|
Cytokines | 1 | 2017 | 775 | 0.460 |
Why?
|
Central Nervous System Neoplasms | 3 | 2019 | 81 | 0.460 |
Why?
|
Intracellular Signaling Peptides and Proteins | 4 | 2019 | 378 | 0.450 |
Why?
|
Signal Transduction | 5 | 2021 | 3233 | 0.440 |
Why?
|
Tissue Plasminogen Activator | 3 | 2019 | 162 | 0.440 |
Why?
|
Longitudinal Studies | 4 | 2021 | 1015 | 0.440 |
Why?
|
Fibrinolytic Agents | 3 | 2019 | 200 | 0.430 |
Why?
|
Algorithms | 1 | 2020 | 1828 | 0.430 |
Why?
|
Cohort Studies | 7 | 2021 | 2759 | 0.420 |
Why?
|
Minimally Invasive Surgical Procedures | 4 | 2022 | 234 | 0.390 |
Why?
|
Humans | 46 | 2024 | 86281 | 0.390 |
Why?
|
Male | 28 | 2021 | 40860 | 0.380 |
Why?
|
Female | 28 | 2021 | 44405 | 0.360 |
Why?
|
Machine Learning | 3 | 2021 | 232 | 0.360 |
Why?
|
Proto-Oncogene Proteins | 4 | 2023 | 645 | 0.350 |
Why?
|
Inflammation Mediators | 2 | 2021 | 154 | 0.350 |
Why?
|
Adult | 19 | 2023 | 25577 | 0.340 |
Why?
|
Disease Progression | 5 | 2021 | 1531 | 0.340 |
Why?
|
Young Adult | 10 | 2021 | 5961 | 0.330 |
Why?
|
Thrombolytic Therapy | 2 | 2021 | 220 | 0.310 |
Why?
|
Endothelial Cells | 8 | 2024 | 427 | 0.300 |
Why?
|
Mice, Transgenic | 7 | 2019 | 1537 | 0.290 |
Why?
|
Protein Kinase Inhibitors | 3 | 2019 | 589 | 0.290 |
Why?
|
Mice | 15 | 2022 | 11313 | 0.290 |
Why?
|
Adolescent | 10 | 2020 | 8968 | 0.280 |
Why?
|
Follow-Up Studies | 5 | 2023 | 3616 | 0.270 |
Why?
|
Child, Preschool | 7 | 2020 | 3608 | 0.270 |
Why?
|
Mutation | 6 | 2023 | 3952 | 0.270 |
Why?
|
Middle Aged | 15 | 2021 | 24957 | 0.270 |
Why?
|
Stroke | 3 | 2023 | 959 | 0.260 |
Why?
|
Image Processing, Computer-Assisted | 4 | 2019 | 1200 | 0.260 |
Why?
|
Propranolol | 2 | 2022 | 45 | 0.250 |
Why?
|
Membrane Proteins | 3 | 2021 | 1194 | 0.250 |
Why?
|
Gastrointestinal Microbiome | 3 | 2020 | 451 | 0.250 |
Why?
|
Animals | 19 | 2022 | 26518 | 0.240 |
Why?
|
Astrocytes | 2 | 2021 | 139 | 0.240 |
Why?
|
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 3 | 2020 | 36 | 0.240 |
Why?
|
Circulating MicroRNA | 1 | 2022 | 12 | 0.220 |
Why?
|
Prospective Studies | 6 | 2023 | 4194 | 0.210 |
Why?
|
Contrast Media | 4 | 2023 | 1076 | 0.210 |
Why?
|
Aged | 12 | 2021 | 18353 | 0.200 |
Why?
|
Lipopolysaccharide Receptors | 2 | 2018 | 23 | 0.200 |
Why?
|
Cerebral Veins | 1 | 2021 | 30 | 0.200 |
Why?
|
Child | 7 | 2020 | 6913 | 0.200 |
Why?
|
Adrenergic beta-1 Receptor Antagonists | 1 | 2021 | 9 | 0.200 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2021 | 56 | 0.200 |
Why?
|
Acute Disease | 3 | 2020 | 824 | 0.200 |
Why?
|
ADAMTS5 Protein | 1 | 2020 | 4 | 0.200 |
Why?
|
Versicans | 1 | 2020 | 6 | 0.200 |
Why?
|
PubMed | 1 | 2020 | 12 | 0.190 |
Why?
|
Perfusion Imaging | 1 | 2021 | 50 | 0.190 |
Why?
|
Time Factors | 4 | 2020 | 5198 | 0.190 |
Why?
|
Socioeconomic Factors | 1 | 2023 | 567 | 0.190 |
Why?
|
Glioma | 1 | 2023 | 285 | 0.190 |
Why?
|
Brain Stem | 1 | 2021 | 165 | 0.190 |
Why?
|
Toll-Like Receptor 4 | 2 | 2019 | 88 | 0.190 |
Why?
|
Hematoma | 2 | 2019 | 104 | 0.190 |
Why?
|
Mice, Knockout | 6 | 2021 | 1918 | 0.190 |
Why?
|
Time-to-Treatment | 1 | 2021 | 97 | 0.180 |
Why?
|
Endothelium, Vascular | 2 | 2020 | 435 | 0.180 |
Why?
|
Simvastatin | 2 | 2019 | 106 | 0.180 |
Why?
|
Neurotoxins | 1 | 2020 | 49 | 0.180 |
Why?
|
Proof of Concept Study | 1 | 2019 | 38 | 0.180 |
Why?
|
Plasma Cells | 1 | 2020 | 80 | 0.180 |
Why?
|
Botulinum Toxins, Type A | 1 | 2020 | 42 | 0.180 |
Why?
|
Chronic Disease | 3 | 2020 | 968 | 0.180 |
Why?
|
Kruppel-Like Transcription Factors | 4 | 2021 | 93 | 0.180 |
Why?
|
Autoantigens | 1 | 2020 | 127 | 0.170 |
Why?
|
Root Cause Analysis | 1 | 2018 | 3 | 0.170 |
Why?
|
Protein C | 1 | 2018 | 5 | 0.170 |
Why?
|
Thrombomodulin | 1 | 2018 | 7 | 0.170 |
Why?
|
Cerebral Intraventricular Hemorrhage | 1 | 2018 | 9 | 0.170 |
Why?
|
Case-Control Studies | 3 | 2021 | 1801 | 0.170 |
Why?
|
Autoantibodies | 1 | 2020 | 267 | 0.170 |
Why?
|
Zinc | 1 | 2019 | 91 | 0.170 |
Why?
|
Cation Transport Proteins | 1 | 2019 | 64 | 0.170 |
Why?
|
Cerebrovascular Circulation | 2 | 2021 | 212 | 0.160 |
Why?
|
Interleukin-1beta | 1 | 2018 | 78 | 0.160 |
Why?
|
Depressive Disorder, Major | 1 | 2020 | 158 | 0.160 |
Why?
|
Caenorhabditis elegans Proteins | 1 | 2019 | 108 | 0.160 |
Why?
|
Thrombospondin 1 | 1 | 2017 | 21 | 0.160 |
Why?
|
Clinical Trials as Topic | 1 | 2023 | 1168 | 0.160 |
Why?
|
Gastrointestinal Tract | 1 | 2019 | 191 | 0.160 |
Why?
|
Observer Variation | 2 | 2016 | 601 | 0.150 |
Why?
|
Matrix Metalloproteinase 2 | 1 | 2017 | 44 | 0.150 |
Why?
|
Area Under Curve | 1 | 2018 | 334 | 0.150 |
Why?
|
Sensitivity and Specificity | 2 | 2021 | 1987 | 0.150 |
Why?
|
MicroRNAs | 1 | 2022 | 534 | 0.150 |
Why?
|
Social Dominance | 1 | 2017 | 30 | 0.150 |
Why?
|
Interleukin-6 | 1 | 2018 | 255 | 0.150 |
Why?
|
Receptors, Cell Surface | 1 | 2018 | 286 | 0.150 |
Why?
|
Permeability | 3 | 2021 | 133 | 0.140 |
Why?
|
Histological Techniques | 1 | 2016 | 35 | 0.140 |
Why?
|
Iodine | 1 | 2016 | 40 | 0.140 |
Why?
|
Orientation | 1 | 2017 | 119 | 0.140 |
Why?
|
Cluster Analysis | 1 | 2017 | 369 | 0.140 |
Why?
|
Reproducibility of Results | 3 | 2019 | 2699 | 0.140 |
Why?
|
Mice, Inbred C57BL | 5 | 2020 | 3087 | 0.140 |
Why?
|
Enzyme Inhibitors | 1 | 2019 | 632 | 0.140 |
Why?
|
Bayes Theorem | 3 | 2022 | 360 | 0.140 |
Why?
|
ROC Curve | 1 | 2018 | 752 | 0.140 |
Why?
|
Demography | 1 | 2016 | 177 | 0.130 |
Why?
|
Organ Size | 1 | 2016 | 363 | 0.130 |
Why?
|
Genetic Therapy | 1 | 2017 | 342 | 0.130 |
Why?
|
Anticoagulants | 1 | 2018 | 404 | 0.130 |
Why?
|
C-Reactive Protein | 1 | 2016 | 190 | 0.130 |
Why?
|
B-Lymphocytes | 2 | 2018 | 724 | 0.130 |
Why?
|
Leukocytes | 1 | 2016 | 202 | 0.130 |
Why?
|
Social Behavior | 1 | 2017 | 294 | 0.120 |
Why?
|
Immunity, Innate | 1 | 2017 | 405 | 0.120 |
Why?
|
Treatment Outcome | 6 | 2023 | 7949 | 0.120 |
Why?
|
Hypertension | 1 | 2022 | 1139 | 0.110 |
Why?
|
Prognosis | 1 | 2021 | 3669 | 0.110 |
Why?
|
Apoptosis | 1 | 2019 | 1678 | 0.110 |
Why?
|
MAP Kinase Kinase Kinase 3 | 2 | 2021 | 12 | 0.100 |
Why?
|
Perfusion | 2 | 2021 | 202 | 0.100 |
Why?
|
Neurosurgery | 2 | 1982 | 84 | 0.090 |
Why?
|
Gene Expression Profiling | 3 | 2024 | 1381 | 0.090 |
Why?
|
Phenotype | 3 | 2021 | 2375 | 0.090 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2019 | 378 | 0.080 |
Why?
|
Zebrafish Proteins | 2 | 2021 | 144 | 0.080 |
Why?
|
Lipopolysaccharides | 2 | 2020 | 285 | 0.080 |
Why?
|
Zebrafish | 2 | 2021 | 307 | 0.080 |
Why?
|
HEK293 Cells | 2 | 2020 | 615 | 0.070 |
Why?
|
Neoplasms | 2 | 2021 | 2889 | 0.070 |
Why?
|
Neurosurgical Procedures | 2 | 2020 | 213 | 0.070 |
Why?
|
Disease Susceptibility | 2 | 2017 | 192 | 0.070 |
Why?
|
Professional Practice | 3 | 1981 | 45 | 0.070 |
Why?
|
Pilot Projects | 2 | 2020 | 837 | 0.070 |
Why?
|
Double-Blind Method | 2 | 2019 | 1822 | 0.060 |
Why?
|
Combined Modality Therapy | 2 | 2019 | 1680 | 0.060 |
Why?
|
Genotype | 2 | 2021 | 1850 | 0.060 |
Why?
|
Aging | 2 | 2020 | 689 | 0.060 |
Why?
|
Brain Mapping | 2 | 2017 | 547 | 0.060 |
Why?
|
Blood-Brain Barrier | 1 | 2023 | 69 | 0.060 |
Why?
|
Specialization | 1 | 1982 | 65 | 0.050 |
Why?
|
Gain of Function Mutation | 1 | 2021 | 13 | 0.050 |
Why?
|
Water | 1 | 2023 | 274 | 0.050 |
Why?
|
Commission on Professional and Hospital Activities | 1 | 1981 | 1 | 0.050 |
Why?
|
Mechanistic Target of Rapamycin Complex 1 | 1 | 2021 | 29 | 0.050 |
Why?
|
Human Umbilical Vein Endothelial Cells | 1 | 2021 | 63 | 0.050 |
Why?
|
Medicine | 1 | 1982 | 89 | 0.050 |
Why?
|
Nitric Oxide Synthase Type III | 1 | 2021 | 88 | 0.050 |
Why?
|
Cyclooxygenase 2 | 1 | 2021 | 99 | 0.050 |
Why?
|
Medical Audit | 1 | 1981 | 41 | 0.050 |
Why?
|
G-Protein-Coupled Receptor Kinase 2 | 1 | 2021 | 22 | 0.050 |
Why?
|
Loss of Function Mutation | 1 | 2021 | 42 | 0.050 |
Why?
|
ADAMTS4 Protein | 1 | 2020 | 4 | 0.050 |
Why?
|
Receptors, Adrenergic, beta-2 | 1 | 2021 | 36 | 0.050 |
Why?
|
ADAMTS1 Protein | 1 | 2020 | 6 | 0.050 |
Why?
|
Patient Participation | 1 | 2023 | 216 | 0.050 |
Why?
|
Mice, Inbred DBA | 1 | 2020 | 148 | 0.050 |
Why?
|
Cyclic N-Oxides | 1 | 2020 | 33 | 0.050 |
Why?
|
Craniotomy | 1 | 2021 | 88 | 0.050 |
Why?
|
Cholecalciferol | 1 | 2020 | 35 | 0.050 |
Why?
|
Plasma | 1 | 2020 | 50 | 0.050 |
Why?
|
Tumor Microenvironment | 1 | 2024 | 415 | 0.050 |
Why?
|
Vimentin | 1 | 2020 | 44 | 0.050 |
Why?
|
Spin Labels | 1 | 2020 | 102 | 0.050 |
Why?
|
Tubulin | 1 | 2020 | 58 | 0.050 |
Why?
|
Proteolysis | 1 | 2020 | 100 | 0.050 |
Why?
|
Sequence Analysis, DNA | 1 | 2023 | 853 | 0.050 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2021 | 151 | 0.050 |
Why?
|
Myosin Heavy Chains | 1 | 2020 | 88 | 0.050 |
Why?
|
Risk Factors | 2 | 2022 | 5397 | 0.050 |
Why?
|
Self Report | 1 | 2021 | 287 | 0.050 |
Why?
|
Sirolimus | 1 | 2021 | 169 | 0.050 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2021 | 182 | 0.050 |
Why?
|
Dextran Sulfate | 1 | 2019 | 68 | 0.050 |
Why?
|
Nitric Oxide | 1 | 2021 | 277 | 0.050 |
Why?
|
Animals, Newborn | 1 | 2021 | 509 | 0.040 |
Why?
|
White Matter | 1 | 2020 | 80 | 0.040 |
Why?
|
Metagenomics | 1 | 2020 | 83 | 0.040 |
Why?
|
Programmed Cell Death 1 Receptor | 1 | 2021 | 159 | 0.040 |
Why?
|
Migraine Disorders | 1 | 2020 | 40 | 0.040 |
Why?
|
Mitogen-Activated Protein Kinase 7 | 1 | 2019 | 21 | 0.040 |
Why?
|
Antidepressive Agents | 1 | 2020 | 106 | 0.040 |
Why?
|
DNA, Bacterial | 1 | 2020 | 236 | 0.040 |
Why?
|
rhoA GTP-Binding Protein | 1 | 2019 | 83 | 0.040 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2020 | 241 | 0.040 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2019 | 74 | 0.040 |
Why?
|
Toll-Like Receptors | 1 | 2020 | 92 | 0.040 |
Why?
|
Endothelial Protein C Receptor | 1 | 2018 | 4 | 0.040 |
Why?
|
Patient Selection | 1 | 2023 | 685 | 0.040 |
Why?
|
Gene Deletion | 1 | 2020 | 328 | 0.040 |
Why?
|
Otolaryngology | 1 | 1979 | 53 | 0.040 |
Why?
|
Mutagenesis | 1 | 2019 | 199 | 0.040 |
Why?
|
Genetic Association Studies | 1 | 2020 | 294 | 0.040 |
Why?
|
Aged, 80 and over | 2 | 2020 | 6481 | 0.040 |
Why?
|
Animals, Genetically Modified | 1 | 2019 | 181 | 0.040 |
Why?
|
Feces | 1 | 2020 | 316 | 0.040 |
Why?
|
Occludin | 1 | 2018 | 63 | 0.040 |
Why?
|
Ligands | 1 | 2019 | 433 | 0.040 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2019 | 318 | 0.040 |
Why?
|
Muscle Proteins | 1 | 2019 | 132 | 0.040 |
Why?
|
Blood Coagulation | 1 | 2018 | 91 | 0.040 |
Why?
|
MAP Kinase Signaling System | 1 | 2019 | 192 | 0.040 |
Why?
|
Sequence Alignment | 1 | 2019 | 351 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2018 | 169 | 0.040 |
Why?
|
Dexamethasone | 1 | 2019 | 326 | 0.040 |
Why?
|
Models, Neurological | 1 | 2021 | 405 | 0.040 |
Why?
|
Administration, Oral | 1 | 2019 | 683 | 0.040 |
Why?
|
Recovery of Function | 1 | 2019 | 272 | 0.040 |
Why?
|
Disease Management | 1 | 2020 | 327 | 0.040 |
Why?
|
Logistic Models | 1 | 2021 | 1184 | 0.040 |
Why?
|
Chronic Pain | 1 | 2020 | 145 | 0.040 |
Why?
|
Gram-Negative Bacteria | 1 | 2017 | 35 | 0.040 |
Why?
|
Catheters | 1 | 2017 | 68 | 0.040 |
Why?
|
Magnetic Resonance Angiography | 1 | 2020 | 261 | 0.040 |
Why?
|
Phantoms, Imaging | 1 | 2019 | 426 | 0.040 |
Why?
|
Germ-Free Life | 1 | 2017 | 69 | 0.040 |
Why?
|
Injections, Intravenous | 1 | 2017 | 243 | 0.040 |
Why?
|
Caenorhabditis elegans | 1 | 2019 | 222 | 0.040 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2019 | 380 | 0.040 |
Why?
|
Feasibility Studies | 1 | 2019 | 751 | 0.040 |
Why?
|
Intestines | 1 | 2020 | 407 | 0.040 |
Why?
|
Attitude of Health Personnel | 1 | 1982 | 636 | 0.040 |
Why?
|
Microfilament Proteins | 1 | 2018 | 206 | 0.040 |
Why?
|
Colitis | 1 | 2019 | 236 | 0.040 |
Why?
|
Cerebellum | 1 | 2018 | 247 | 0.040 |
Why?
|
Phosphorylation | 1 | 2019 | 1101 | 0.040 |
Why?
|
RNA Interference | 1 | 2017 | 368 | 0.040 |
Why?
|
Carrier Proteins | 1 | 2019 | 672 | 0.030 |
Why?
|
Pattern Recognition, Visual | 1 | 2017 | 151 | 0.030 |
Why?
|
Prefrontal Cortex | 1 | 2017 | 129 | 0.030 |
Why?
|
Quality of Life | 1 | 2023 | 1575 | 0.030 |
Why?
|
Epithelial Cells | 1 | 2019 | 662 | 0.030 |
Why?
|
RNA, Messenger | 1 | 2021 | 1975 | 0.030 |
Why?
|
Age Factors | 2 | 2016 | 1842 | 0.030 |
Why?
|
Photic Stimulation | 1 | 2017 | 493 | 0.030 |
Why?
|
Intestinal Mucosa | 1 | 2019 | 788 | 0.030 |
Why?
|
Risk Assessment | 1 | 2021 | 2253 | 0.030 |
Why?
|
Models, Biological | 1 | 2020 | 1748 | 0.030 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2017 | 663 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 1 | 2021 | 2267 | 0.030 |
Why?
|
Cells, Cultured | 1 | 2017 | 2810 | 0.030 |
Why?
|
Anti-Bacterial Agents | 1 | 2017 | 739 | 0.030 |
Why?
|
Biomarkers, Tumor | 1 | 2020 | 1461 | 0.030 |
Why?
|
T-Lymphocytes | 1 | 2018 | 1195 | 0.030 |
Why?
|
Brain Ischemia | 1 | 2015 | 397 | 0.020 |
Why?
|
Primary Health Care | 3 | 1982 | 339 | 0.020 |
Why?
|
United States | 4 | 1982 | 6637 | 0.020 |
Why?
|
Task Performance and Analysis | 2 | 1981 | 86 | 0.010 |
Why?
|
Practice Management, Medical | 2 | 1979 | 24 | 0.010 |
Why?
|
Neurology | 1 | 1982 | 69 | 0.010 |
Why?
|
Diagnostic Services | 1 | 1979 | 3 | 0.010 |
Why?
|
Organizational Affiliation | 1 | 1979 | 6 | 0.010 |
Why?
|
Otorhinolaryngologic Diseases | 1 | 1979 | 8 | 0.010 |
Why?
|
Therapeutics | 1 | 1979 | 12 | 0.010 |
Why?
|
Rural Health | 1 | 1979 | 20 | 0.010 |
Why?
|
Urban Health | 1 | 1979 | 55 | 0.010 |
Why?
|
Certification | 1 | 1979 | 58 | 0.010 |
Why?
|
Patients | 1 | 1979 | 100 | 0.010 |
Why?
|
Dermatology | 1 | 1978 | 35 | 0.010 |
Why?
|
Referral and Consultation | 1 | 1979 | 326 | 0.010 |
Why?
|
Sex Factors | 1 | 1979 | 1053 | 0.010 |
Why?
|
Infant | 2 | 1979 | 3036 | 0.010 |
Why?
|
Infant, Newborn | 1 | 1979 | 2369 | 0.010 |
Why?
|
Ambulatory Care | 1 | 1978 | 180 | 0.000 |
Why?
|
Skin Diseases | 1 | 1978 | 166 | 0.000 |
Why?
|